Robert Stein

Dr. Stein brings over 35 years of biopharmaceutical industry, currently serving as Chief Medical Officer of Protagenic Therapeutics and Executive Vice President of Research and Development of MINDEX. He previously served as President of R&D at Agenus Inc. where he lead Agenus’ research, preclinical development and translational medicine functions. Dr. Stein also previously played a pivotal role in bringing several products to the market including Sustiva®, Fablyn®, Viviant®, PanRetin®, TargRetin®, Promacta® and Eliquis®. He has also held executive management positions at Ligand Pharmaceuticals, DuPont Merck, Incyte Pharmaceuticals, Roche Palo Alto and KineMed. Dr. Stein holds an MD and a PhD in Physiology & Pharmacology from Duke University.